Analogues of erectile dysfunction drugs: an under-recognised threat

WT Poon, YH Lam, CK Lai, Albert YW Chan, Tony WL Mak
Hospital Authority Toxicology Reference Laboratory, Princess Margaret Hospital, Laichikok, Hong Kong

OBJECTIVES. To investigate the problem of drug analogue adulteration in male erectile dysfunction health products.

DESIGN. Survey of over-the-counter male erectile dysfunction health products available in convenience stores and pharmacies in Hong Kong.

SETTING. Tertiary referral centre for clinical toxicology analysis in Hong Kong.

MAIN OUTCOME MEASURES. The pattern and extent of adulteration of male erectile dysfunction health products with sildenafil, tadalafil, and vardenafil as well as their structurally modified analogues.

RESULTS. Of 26 products studied, one (4%) was found to contain undeclared sildenafil, while 14 (54%) contained drug analogues of different kinds. The latter included acetildenafil, hydroxyacetildenafil, hydroxyhomosildenafil, and piperidenafil. The first three were analogues of sildenafil and the last was an analogue of vardenafil. One young patient presented with ataxia after taking an acetildenafil-containing product.

CONCLUSIONS. The positive rate of concealed drug analogues in male erectile dysfunction health products is alarmingly high. Such analogues are difficult to detect by ordinary laboratory methods, and might be used in an attempt to evade regulatory inspection. Without going through the stringent drug testing process, the adverse effects of these chemicals remain largely unknown and unpredictable. Effective surveillance system and control measures are needed urgently. The medical profession and the public should be alerted to this under-recognised threat.

Hong Kong Med J 2007;13:359-63

Key words: Designer drugs; Impotence; Sildenafil; Vardenafil